subject: Export Growth For The First Time Negative Growth Step On The Gas Tight Upgrading Api - Api, Import [print this page] Face for the first 3 months API The overall trend of declining trade, the Canton Fair on medicine shrinking export orders, and international economic boom of the landslide, API business and industry should do about it? This is the just-concluded 62nd China International Pharmaceutical / Intermediate / Packaging / Equipment Spring Fair-discussed topic, but this fair, "science and technology innovation and meet challenges, boost domestic demand and promote industrial upgrading" theme, also echoes the situation.
However, the parties still at the bulk drug industry in 2009 is optimistic: in the international market, domestic major enterprises in a dominant position API is still hard to shake; the domestic market in the context of the new medical reform will be welcome to a greater expansion opportunities.
"Crises" in the search "machine"
Reporters heard a word most is the "crisis." Global Migration API production capacity, new medical reform and other favorable factors under the market expansion, will undoubtedly be another pattern of bulk drugs industry restructuring and further development opportunities. However, the domestic raw material drug companies, the low-level duplicated construction and the resultant Environmental protection Pressure, is still hanging in the enterprise's head "sword of Damocles"; In addition, growing international trade friction is also a bulk drug market, a major test.
"Excess capacity, purchasing power compression, market instability and rising trade protectionism, many companies have brought to business risk. In addition, RMB appreciation, rising raw material prices, labor costs rise under the influence of objective factors such as rely on labor-intensive, economies of scale reduce the cost of the pharmaceutical industry has been driven close to the limit. "China Chemical Pharmaceutical Industry Association, vice chairman of the Committee of Experts says Shen Yin Kyi.
In the domestic market, around the start of the competition remains fierce price. "API changing market suffered a lot of pit enterprises, especially small and medium enterprises." Health Net's chief researcher Hui-Fang Wu at the forum points to the aspirations of many companies. Hui-Fang Wu said that the new medical reform context, the preparation of the raw drug market, business was very confused.
It is noteworthy that, in the new Medical reform Held after the publication of this fair, the face of new opportunities and new challenges, "Technology innovation, transformation and upgrade," the core of many exhibitors consensus.
"The future trend of bulk drugs market is certainly not flat, but with the guidance of national policy, the market will become more standardized, advantages corporate growth will accelerate." Shijiazhuang Pharmaceutical Group Chairman, said Cai Dongcheng, rational judged the market and technology innovation to improve the only way to market competitiveness, companies that we act fast, active use of some of the country's policies to encourage innovation, enhance technical joint research. "Some small and medium manufacturing enterprises Pharmaceutical Packaging Irrational structure of corporate and product preparation production enterprises, the government should attach great importance to public relations, cost savings, while accurately identifying market segments, the joint reorganization of the way to go. "
Shen Yin Kyi also said that Antibiotic Class, vitamins, antipyretic and analgesic drugs varieties, and the short term there is no substitute for our country's international status, but anti-risk, Seizing an opportunity, innovation is the only way to upgrade.
